Carumonam
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00705 |
| CAS | 87638-04-8 |
| Molecular Weight | 466.40 |
| Molecular Formula | C12H14N6O10S2 |
| Purity | 95% |
Online Inquiry
Description
It is produced by the strain of Monobactams. As well as Azthreonam, it has excellent curative effect on aerobic gram-negative bacteria (including Pseudomonas aeruginosa) infection, but no effect on gram-positive bacteria and anaerobic bacteria.
Specification
| Related CAS | 86832-68-0 (disodium salt) |
| Synonyms | Carumonamum; AMA 1080; (Z)-Carumonam; 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid; CRMN; CARUMONAM |
| IUPAC Name | 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2S,3S)-2-(carbamoyloxymethyl)-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid |
| Canonical SMILES | C1=C(N=C(S1)N)C(=NOCC(=O)O)C(=O)NC2C(N(C2=O)S(=O)(=O)O)COC(=O)N |
| InChI | InChI=1S/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7-/t5-,8+/m1/s1 |
| InChI Key | UIMOJFJSJSIGLV-JNHMLNOCSA-N |
Properties
| Appearance | Colorless Crystalline Powder |
| Antibiotic Activity Spectrum | Gram-negative bacteria |
| Density | 2.13±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO |
Reference Reading
1.[Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J1, Oguri T, Hiramatsu N, Akiyama K, Koyama T. Jpn J Antibiot. 2003 Oct;56(5):458-96.
As a post-marketing surveillance, the in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates were yearly evaluated and compared with those of other cephems, oxacephems, carbapenems, monobactams, and penicillins. Changes in CZOP susceptibility among bacteria were also evaluated with the bacterial resistance ratio calculated from the breakpoint MIC. Twenty-five species (4,154 strains) of Gram-negative bacteria were isolated from the clinical materials annually collected from 1996 to 2001, and consisted of Moraxella (Branhamella) catarrhalis, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Serratia marcescens, Serratia liquefaciens, Citrobacter freundii, Citrobacter koseri, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia spp., Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas putida, Acinetobacter baumannii, Acinetobacter Iwoffii, Burkholderia cepacia, Stenotrophomonas maltophilia, Bacteroides fragilis group, and Prevotella/Porphyromonas.
2.[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility].
Kumamoto Y1, Tsukamoto T, Matsukawa M, Kunishima Y, Hirose T, Shigeta S, Yamaguchi O, Ishibashi K, Suzutani T, Yoshida H, Imafuku Y, Murai M, Watanabe K, Kobayashi Y, Uchida H, Matsuda S, Sato S, Fujime M, Fujita K, Igari J, Oguri T, Yamaguchi K, Furuya N, Deguchi T, Ishihara S, Ooe H, Oka T, Kitamura M, Fukuhara Y, Kamidono S, Arakawa S, Kumon H, Monden K, Matsumoto T, Muratani T, Naito S, Egashira T, Konishi T, Kohno S, Hirakata Y, Kondo A, Matsuda J, Nakano M. Jpn J Antibiot. 2006 Aug;59(4):217-315.
The bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa) isolated from patients diagnosed as urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2004 and July 2005. The susceptibilities of these bacteria to various antimicrobial agents were measured. The bacteria were divided into 2 groups consisting of uncomplicated UTIs and complicated UTIs (with and without indwelling catheter) based on their isolation origins. The results were compared with those obtained between 1995 and 2003. The drug sensitivity of S. aureus in this year was similar to those in up to the previous year and S. aureus showed the best susceptibility to vancomycin (VCM) and arbekacin (ABK). The drug sensitivity of E. faecalis in this year also was similar to those in up to the previous year. The susceptibility of E. coli to cephems in this year was generally good and was similar to those in up to the previous year.
3.Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Bulitta JB1, Duffull SB, Landersdorfer CB, Kinzig M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F. Diagn Microbiol Infect Dis. 2009 Oct;65(2):130-41. doi: 10.1016/j.diagmicrobio.2009.06.018.
Our objectives were to compare the pharmacokinetics (PK) of carumonam, a monobactam, between cystic fibrosis (CF) patients and healthy volunteers and assess its pharmacodynamic profile. We studied 10 adult CF patients and 18 healthy volunteers of similar body size (dose: 2.166 g of carumonam as 15-min intravenous infusion). High performance liquid chromatography with ultraviolet detection (HPLC-UV) was used for drug analysis and NONMEM (ICON, Ellicot City, MD) for population PK and Monte Carlo simulation with targets between > or =20% and 100% free time above MIC (fT > MIC). Unscaled renal clearance was 24% higher in CF patients. Lean body mass and creatinine clearance explained the difference in average clearance and volume of distribution between both subject groups. For a daily dose of 6 g per 70 kg of total body weight, 15-min infusions q8h achieved robust (>90%) probabilities of target attainment (PTAs) (target, 60% fT > MIC) for MICs < or =3 mg/L in CF patients and < or =6 mg/L in healthy volunteers.
4.[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2003). III. Secular changes in susceptibility].
Kumamoto Y1, Tsukamoto T, Matsukawa M, Kunishima Y, Watanabe K, Kobayashi Y, Uchida H, Matsuda S, Hirose T, Sato S, Shigeta S, Fujime M, Fujita K, Yamaguti O, Ishibashi K, Igari J, Suzutani T, Oguri T, Yoshida H, Imafuku Y, Yamaguchi K, Furuya N, Murai M, Deguchi T, Ishihara S, Ooe H, Matsumoto T, Takahashi K, Nishikawa M, Naito S, Egashira T, Konishi T, Oka T, Kitamura M, Kohno S, Fukuhara Y, Hirakata Y, Kondo A, Matsuda J, Nakano M, Kamidono S, Suzuki Y, Arakawa S, Kumon H, Monden K. Jpn J Antibiot. 2005 Dec;58(6):557-654.
The bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa) isolated from 565 patients diagnosed as urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2003 and July 2004. The susceptibilities of these bacteria to various antimicrobial agents were examined. The bacteria were divided into 2 groups consisting of uncomplicated UTIs and complicated UTIs (with and without indwelling catheter) based on their isolation origins. The results were compared with those obtained between 1994 and 2002. The drug sensitivity of S. aureus in this year was similar to those in up to the previous years and S. aureus showed the best susceptibility to vancomycin. The drug sensitivity of E. faecalis in this year also was similar to those in up to the previous years. The drug sensitivity of E. coli in this year was generally good except penicillins and was similar to those in up to the previous years.
Recommended Products
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
